$CURR Update on $20 Million Asset Sale: CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
August 9, 2022 (Globe Newswire)
CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"
, a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update.
As discussed on the call, the Company intends to execute on its strategy of being a broad platform technology company, creating new innovative technology and intellectual property with the intention of monetizing the pipeline and building The Sera Labs brands that build shareholder value.
Below are the recorded call and webcast replay details. This replay will be made available until August 3, 2023.
Conference Call Information:
Webcast Link: https://www.webcaster4.com/Webcast/Page/2906/46305
Teleconference
Replay Numbers: Toll Free: 877-481-4010
(Available until 8/3/23) International: 919-882-2331
Replay Passcode: 46305
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a technology-oriented company with its broad portfolio of patents, CURE partners with pharmaceutical and wellness companies worldwide to develop products and monetize its intellectual property.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs" , a wholly-owned subsidiary of CURE, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology. Sera Labs creates high quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical(TM), Seratopical Revolution(TM) SeraLabs(TM), and Nutri-Strips(TM). Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty and wellness utilizing proprietary technology, Sera Labs products are sold Direct to Consumer as well as in major national drug, grocery chains, convenience stores and mass retailers. Sera Labs also sell products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: http://www.Seratopicalrevolution.com, http://www.Seratopical.com, http://www.Seralabshealth.com and follow Sera Labs on Instagram at @seratopical, as well as Twitter and Facebook.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information
Contacts
Investor Relations
Hanover International Inc.
investor@curepharmaceutical.com
760-564-7400
August 9, 2022 (Globe Newswire)
CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"
, a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update. As discussed on the call, the Company intends to execute on its strategy of being a broad platform technology company, creating new innovative technology and intellectual property with the intention of monetizing the pipeline and building The Sera Labs brands that build shareholder value.
Below are the recorded call and webcast replay details. This replay will be made available until August 3, 2023.
Conference Call Information:
Webcast Link: https://www.webcaster4.com/Webcast/Page/2906/46305
Teleconference
Replay Numbers: Toll Free: 877-481-4010
(Available until 8/3/23) International: 919-882-2331
Replay Passcode: 46305
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a technology-oriented company with its broad portfolio of patents, CURE partners with pharmaceutical and wellness companies worldwide to develop products and monetize its intellectual property.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs"
, a wholly-owned subsidiary of CURE, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology. Sera Labs creates high quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical(TM), Seratopical Revolution(TM) SeraLabs(TM), and Nutri-Strips(TM). Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty and wellness utilizing proprietary technology, Sera Labs products are sold Direct to Consumer as well as in major national drug, grocery chains, convenience stores and mass retailers. Sera Labs also sell products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: http://www.Seratopicalrevolution.com, http://www.Seratopical.com, http://www.Seralabshealth.com and follow Sera Labs on Instagram at @seratopical, as well as Twitter and Facebook. Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information
Contacts
Investor Relations
Hanover International Inc.
investor@curepharmaceutical.com
760-564-7400
1
